Free provider profile
MAZEN ELYAN, MD
Need more providers like MAZEN ELYAN?
See the count and top 3 free, ranked by Medicare billing. Full list $29, included with membership.
Rep intel
What MAZEN ELYAN prescribes and who else does
Top Medicare Part D drugs by claims (public CMS data):
- Humira(Cf) Pen
- Cosentyx Sensoready Pen
- Actemra Actpen
- Enbrel Sureclick
- Rinvoq
Your next referral list starts here
Provider + market indicator
A combined screening indicator—not a provider fraud-risk score. Local plan ratings describe the surrounding market, not this provider’s quality, plan membership or wrongdoing.
Comparing current CMS billing with peers and checking OIG and plan ratings… A new peer comparison can take about a minute.
Practice contact card
Practice phone
859-344-1900
Fax
859-344-4632
Practice address
651 CENTRE VIEW BOULEVARD, CRESTVIEW HILLS, KY, 41017
- Registry updated
- 2019-04-26
- NPI issued
- 2007-01-18
- RepVector retrieved
- 11/20/2026
A recent retrieval can still contain an old address if the provider has not updated their registry record. Website email checks show their own date under Find email.
Registry record
Source: CMS NPPES registry.
651 CENTRE VIEW BOULEVARD, CRESTVIEW HILLS, KY, 41017
859-344-1900
Single practice location
Enumerated 2007-01-18
- — Registration is active in NPPES.
- — Individual clinician record — reachable, but usually not the buyer.
- — Practice phone number is published.
- — Full street address on file for route planning.
- — 3 taxonomies listed — broader service mix.
- — Record last updated 7 years ago.
Medicare Part D prescribing
Source: CMS Medicare Part D Prescribers by Provider, most recent public year.
Part D claims
1,956
Medicare patients
250
Part D drug cost
$1,783,441
Brand-name share
16%
of this prescriber's Part D claims
| Drug | Claims | Medicare cost |
|---|---|---|
| Humira(Cf) Pen (Adalimumab) | 59 | $393,453 |
| Cosentyx Sensoready Pen (Secukinumab) | 33 | $222,626 |
| Enbrel Sureclick (Etanercept) | 19 | $162,716 |
| Xeljanz Xr (Tofacitinib Citrate) | 16 | $134,010 |
| Actemra Actpen (Tocilizumab) | 31 | $121,188 |
| Rinvoq (Upadacitinib) | 18 | $114,586 |
| Taltz Autoinjector (Ixekizumab) | 13 | $88,306 |
| Simponi (Golimumab) | 11 | $67,467 |
Want their full drug mix and peer benchmark? Run the free Part D prescriber lookup.
Latest Medicare Part B billing
CMS Physician and Other Practitioners, by Provider and Service. New published billing years are detected daily, using the same release as the Billing analyst and risk maps.
Loading the latest published CMS billing file…
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
Checking Open Payments…
Industry payments across KY — which companies pay providers there.
- Registry data comes straight from CMS NPPES, which lists registration, not activity — a listed practice may have moved or closed.
- Part D covers Medicare prescription drug enrollees only. Commercial, Medicaid and cash-pay prescribing is not included, so these figures are a floor on real volume, not the whole picture.
- CMS publishes the Part D file annually, roughly two years behind the prescribing year. Drugs with 10 or fewer claims are suppressed.
